Literature DB >> 2985280

A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus.

M Boshart, F Weber, G Jahn, K Dorsch-Häsler, B Fleckenstein, W Schaffner.   

Abstract

A strong transcription enhancer was identified in the genomic DNA (235 kb) of human cytomegalovirus (HCMV), a ubiquitous and severe pathogen of the herpesvirus group. Cotransfection of enhancerless SV40 DNA with randomly fragmented HCMV DNA yielded two SV40-HCMV recombinant viruses that had incorporated overlapping segments of HCMV DNA to substitute for the missing SV40 enhancer. Within HCMV, these enhancer sequences are located upstream of the transcription initiation site of the major immediate-early gene, between nucleotides -118 and -524. Deletion studies with the HCMV enhancer, which harbors a variety of repeated sequence motifs, show that different subsets of this enhancer can substitute for the SV40 enhancer. The HCMV enhancer, which seems to have little cell type or species preference, is severalfold more active than the SV40 enhancer. It is the strongest enhancer we have analyzed so far, a property that makes it a useful component of eukaryotic expression vectors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985280     DOI: 10.1016/s0092-8674(85)80025-8

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  436 in total

1.  A strong negative transcriptional regulatory region between the human cytomegalovirus UL127 gene and the major immediate-early enhancer.

Authors:  C A Lundquist; J L Meier; M F Stinski
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors.

Authors:  D Armentano; M P Smith; C C Sookdeo; J Zabner; M A Perricone; J A St George; S C Wadsworth; R J Gregory
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

3.  Identification of a boundary domain adjacent to the potent human cytomegalovirus enhancer that represses transcription of the divergent UL127 promoter.

Authors:  A Angulo; D Kerry; H Huang; E M Borst; A Razinsky; J Wu; U Hobom; M Messerle; P Ghazal
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Random, asynchronous, and asymmetric transcriptional activity of enhancer-flanking major immediate-early genes ie1/3 and ie2 during murine cytomegalovirus latency in the lungs.

Authors:  N K Grzimek; D Dreis; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  In vivo replication of recombinant murine cytomegalovirus driven by the paralogous major immediate-early promoter-enhancer of human cytomegalovirus.

Authors:  N K Grzimek; J Podlech; H P Steffens; R Holtappels; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  Repression of human cytomegalovirus gene expression associated with a novel immediate early regulatory region binding factor.

Authors:  S L Shelbourn; S K Kothari; J G Sissons; J H Sinclair
Journal:  Nucleic Acids Res       Date:  1989-11-25       Impact factor: 16.971

7.  Efficient cationic lipid-mediated delivery of antisense oligonucleotides into eukaryotic cells: down-regulation of the corticotropin-releasing factor receptor.

Authors:  F Shi; A Nomden; V Oberle; J B Engberts; D Hoekstra
Journal:  Nucleic Acids Res       Date:  2001-05-15       Impact factor: 16.971

8.  Mechanisms of inhibition of nuclear hormone receptor-dependent hepatitis B virus replication by hepatocyte nuclear factor 3beta.

Authors:  Hong Tang; Alan McLachlan
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Molecular cloning of DNA sequences from cervical intraepithelial neoplasia that hybridize to human cytomegalovirus DNA.

Authors:  K Fletcher; J C Macnab
Journal:  Virus Genes       Date:  1989-08       Impact factor: 2.332

10.  Hypoxia in renal disease with proteinuria and/or glomerular hypertension.

Authors:  Tetsuhiro Tanaka; Toshio Miyata; Reiko Inagi; Toshiro Fujita; Masaomi Nangaku
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.